Company

ViGenCell Inc.

ViGenCell develops immune cell therapies for cancer and other diseases.

About

ViGenCell Inc. is a Seoul-based biotechnology company founded in 2013 as a subsidiary of Catholic University Technology Holdings Co., Ltd. It develops therapies using T cells, myeloid-derived suppressor cells, and gamma-delta T cells for conditions including leukemia, lymphoma, atopic dermatitis, and graft-versus-host disease. In December 2024, GAEUN GLOBAL Co.,Ltd acquired an 11.37% minority stake from Boryung Biopharma Co., Ltd. CEO Kim Tae-gyu leads the firm.

2Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in